ACP, Pri-Med to train opioid prescribers

The American College of Physicians (ACP), partnered with Pri-Med, has been awarded an independent educational grant, bestowed upon them by the REMS Program Companies (RPC) — a lump sum meant to be used in the development and implementation of a training program aimed at educating physicians and clinicians about safety and efficacy when prescribing opioids.

Following the lead of the Food and Drug Administration’s Blueprint for Prescriber Education for Extended-Release and Long-Acting Opioid Analgesics, the ACP-Pri-Med grant endeavor will train primary care physicians who wish to recommend and prescribe ER/LA opioids for patients with chronic pain to safely do so by today’s standards.

“It is an honor to be one of the first accredited CME providers taking part in this inaugural education initiative,” said Marissa Seligman, PharmD chief compliance, clinical and regulatory affairs officer and senior vice president, pmiCME, the accredited education division of DBC Pri-Med, in a news release. “This grant enables Pri-Med and ACP to offer a multi-channel series of live courses and a digital forum to educate clinicians about proper and safe use of opioids, equipping them with the fundamental tools and resources to provide the best care and outcomes for their patients.”

“The comprehensive curriculum, backed by the governing body of the FDA, will help advance proper and safe prescribing practices seen in this space,” added Patrick C. Alguire, MD, FACP, ACP’s senior vice president for Medical Education. “Our commitment to providing quality clinician education alongside our partner, Pri-Med, is our number one goal. We are proud to launch this program and help reduce the knowledge gap within the clinician community.”

On June 15, 2013 the program curriculum will be released online, with access points at and Self-assessment tools meant “to measure the educational process and help increase safe prescribing of ER/LA opioids, as well as improve processes to more effectively monitor patient evaluation treatments,” will be provided through the system to the nearly 122,000-plus ER/LA opioid prescribers.